Maxigen Biotech Inc. reported consolidated revenue results for the month and year to date ended April 2022. On a consolidated basis, revenues for April 2022 were approximately TWD 39.471 million, an increase of 31.93% over the same period in 2021.

Revenues for January through April 2022 totaled TWD 162.733 million, an increase of 15.47% compared to the TWD 140.928 million for the same period in 2021.